20-F: Addex Therapeutics 2025 Annual Report Analysis

Addex Therapeutics reports a net loss of CHF 6.7 million for 2025 while highlighting substantial doubt regarding its ability to continue as a going concern beyond mid-June 2026.

Summary

• Reported a net loss of CHF 6.7 million for the fiscal year ended December 31, 2025, compared to a net profit of CHF 7.1 million in 2024.
• Cash and cash equivalents stood at CHF 1.6 million as of December 31, 2025.
• Management explicitly states that existing cash is sufficient only through mid-June 2026, raising substantial doubt about the company's ability to continue as a going concern.
• The company is transitioning to an internally developed pipeline, specifically focusing on GABAB PAM for chronic cough and dipraglurant for post-stroke/TBI recovery.
• The company holds a 20% equity interest in Neurosterix US Holdings LLC, which is accounted for using the equity method.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk filing due to the explicit going concern warning, limited cash runway, and the return of a failed clinical program.

Positives

• Successfully completed IND-enabling studies for the GABAB PAM program for substance use disorders in partnership with Indivior.
• Maintained access to research and development staff and infrastructure from Neurosterix Group at zero cost.
• Retained rights to develop GABAB PAM for chronic cough independently.
• Secured an option and collaboration agreement with Sinntaxis AB for dipraglurant in brain injury recovery.

Negatives

• Net loss of CHF 6.7 million for 2025.
• Cash runway is extremely limited, extending only to mid-June 2026.
• Janssen terminated the partnership for ADX71149 in 2025 after the Phase 2 study failed to meet primary endpoints.
• Management identified a material weakness in internal control over financial reporting related to IFRS compliance.
• The company is classified as a Passive Foreign Investment Company (PFIC), which may have adverse tax consequences for U.S. holders.

Risks

• Substantial doubt regarding the ability to continue as a going concern beyond mid-June 2026.
• Significant need for additional capital to fund ongoing development activities.
• Dependence on third-party partners (Indivior) for the development of key assets.
• Potential delisting from Nasdaq if minimum bid price requirements are not maintained.
• Risks associated with being a development-stage company with no products on the market.
• Exposure to currency fluctuation risks as a significant portion of costs are denominated in non-CHF currencies.

Future Outlook

The company plans to focus on advancing its GABAB PAM program for chronic cough and dipraglurant for post-stroke/TBI recovery. Future viability depends on securing additional funding through partnerships, grants, or equity offerings by mid-June 2026.

Management Comments

• Management acknowledges that substantial doubt exists regarding the company's ability to continue as a going concern.
• Management believes that the consolidated financial statements fairly present the financial condition despite identified material weaknesses in internal controls.

Industry Context

StockSavvy.ai notes that Addex is navigating a challenging environment for small-cap biotech firms, characterized by high cash burn and reliance on external partnerships. The pivot toward internal development after the Neurosterix spin-out reflects a strategic attempt to retain more value, though it increases the company's direct operational and capital requirements.

Comparison to Industry Standards

• The company's reliance on equity financing and milestone payments is standard for clinical-stage biotech firms.
• The use of allosteric modulation as a platform technology is a specialized niche, similar to other CNS-focused biotech companies.
• The company's cash runway is significantly shorter than the industry standard of 18-24 months for clinical-stage companies.

Corporate Governance

Legal Proceedings

• No material legal proceedings pending.

Related Party Transactions

• Investment in Stalicla SA in June 2025.
• Service agreement with Neurosterix Group for staff and infrastructure access.

Stakeholder Impact

• Shareholders face significant dilution risk due to the need for additional capital.
• Employees and consultants are impacted by the company's limited financial resources.

Next Steps

• Secure additional funding by mid-June 2026.
• Continue evaluation of ADX71149 for potential new indications.
• Initiate IND-enabling studies for the GABAB PAM chronic cough program.
• Advance dipraglurant for post-stroke/TBI recovery.

Key Dates

Recommendation

The combination of a very short cash runway (mid-June 2026), a going concern warning, and the return of a failed clinical program makes the stock highly speculative and unattractive for most institutional investors.

Keywords

Addex Therapeutics, ADXN, Biotechnology, GABAB PAM, Dipraglurant, Neurosterix, Clinical-stage, SEC Filing, 20-F